N-(3-(oxirane-2-ylmethoxy)phenyl)acetamide | 28763-42-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-(oxirane-2-ylmethoxy)phenyl)acetamide
• 英文别名: N-{3-[(2S)oxiranylmethoxy]phenyl}acetamide；N-[3-(oxiran-2-ylmethoxy)phenyl]acetamide
• CAS: 28763-42-0
• 化学式: C₁₁H₁₃NO₃
• 分子量: 207.229
• InChiKey: RUGBMQVCMWSXJP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  50.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(3-(oxirane-2-ylmethoxy)phenyl)acetamide 、 1-(5-phenyl-thieno[2,3-d]pyrimidine-4-yl)-piperidin-4-ylamine 以 异丙醇 为溶剂， 生成 N-(3-(2-hydroxy-3-(1-(5-phenylthieno[2,3-d]pyrimidin-4-yl)piperidin-4-ylamino)propoxy)phenyl)acetamide
  参考文献：
  名称：

  Thienopyrimidines as β3-adrenoceptor agonists: Hit-to-lead optimization

  摘要：

  Resulting from a vHTS based on a pharmacophore alignment on known beta 3-adrenoceptor ligands, an aryloxypropanolamine scaffold comprising a thienopyrimidine moiety was further optimized as a human beta 3-AR agonist, yielding a lead compound with an excellent cellular activity of EC(50) = 20 pM, selectivity over h beta 1- and h beta 2- adrenoceptors and a promising safety profile. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.08.039
• 作为产物：
  描述：

  环氧溴丙烷 、 N-(3-羟基苯基)乙酰胺 在 potassium carbonate 作用下， 以 丁酮 为溶剂， 生成 N-(3-(oxirane-2-ylmethoxy)phenyl)acetamide
  参考文献：
  名称：

  Thienopyrimidines as β3-adrenoceptor agonists: Hit-to-lead optimization

  摘要：

  Resulting from a vHTS based on a pharmacophore alignment on known beta 3-adrenoceptor ligands, an aryloxypropanolamine scaffold comprising a thienopyrimidine moiety was further optimized as a human beta 3-AR agonist, yielding a lead compound with an excellent cellular activity of EC(50) = 20 pM, selectivity over h beta 1- and h beta 2- adrenoceptors and a promising safety profile. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.08.039

文献信息

• Heterocyclic beta-3 adrenergic receptor agonists
  申请人：American Home Products Corporation

  公开号：US20020028832A1

  公开（公告）日：2002-03-07

  This invention provides compounds of Formula I having the structure 1 U, V, W, X, and Y are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

  这项发明提供了具有结构式I的化合物 1 其中U、V、W、X和Y如前文所定义， 或其药学上可接受的盐，用于治疗或抑制与胰岛素抵抗或高血糖相关的代谢紊乱（通常与肥胖或葡萄糖不耐受有关）、动脉粥样硬化、胃肠道疾病、神经炎症、青光眼、眼压增高和频繁排尿；特别适用于治疗或抑制2型糖尿病。
• Design, Synthesis and Biological Activity Testing of Library of Sphk1 Inhibitors
  作者：Shuangshuang Geng、Haijiao Chen、Yan Li、Ying Li、Jingxiang Pang、Feipeng Zhang、Zhiqiang Qu、Mengjun Li、Na Liu、Qingqiang Yao、Yanling Mu、Bo Liu

  DOI：10.3390/molecules27062020

  日期：——

  Our team discovered a moderate SphK1 inhibitor, SAMS10 (IC50 = 9.8 μM), which was screened by computer-assisted screening. In this study, we developed a series of novel diaryl derivatives with improved antiproliferative activities by modifying the structure of the lead compound SAMS10. A total of 50 new compounds were synthesized. Among these compounds, the most potent compound, named CHJ04022Rb, has

  我们的团队通过计算机辅助筛选发现了一种中度 SphK1 抑制剂SAMS10 (IC 50 = 9.8 μM)。在这项研究中，我们通过改变先导化合物SAMS10的结构，开发了一系列具有改善抗增殖活性的新型二芳基衍生物。共合成了 50 种新化合物。在这些化合物中，最有效的化合物CHJ04022Rb在黑色素瘤 A375 细胞系中具有显着的抗癌活性 (IC 50 = 2.95 μM)。进一步的潜在机制研究表明，CHJ04022R对 PI3K/NF-κB 信号通路具有抑制作用，通过诱导 A375 细胞 G2/M 期阻滞，抑制 A375 细胞的迁移，促进细胞凋亡并发挥抗增殖作用。此外，急性毒性实验表明CHJ04022R在体内表现出良好的安全性。此外，它对裸鼠异种移植瘤的生长表现出剂量依赖性抑制作用。因此，CHJ04022R可能是治疗黑色素瘤的潜在候选药物。